EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”

Marie-Noelle Kronig, Marc Wehrli iD, Diego Salas-Benito, Marcela V Maus iD

Immunological Reviews · 2023-11 · 320 (1) · 100-119

DOI: 10.1111/imr.13273 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 11.09.2023. Verfasst von Marie-Noelle Kronig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Digestive tract cancers (DTC) belong to the most investigated family of tumors. The incidence, prevalence, and mortality rate of DTC remain high, especially for patients with pancreatic cancer. Even though immunotherapy such as immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid cancer types, ICI are still restricted to a very small group of patients and seem to be more efficacious in combination with chemotherapy. Cellular immunotherapy such as CAR T‐cell therapy has entered clinical routine in hematological malignancies with outstanding results. There is growing interest on translating this kind of immunotherapy and success into patients with solid malignancies, such as DTC. This review attempts to describe the major advances in preclinical and clinical research with CAR T cells in DTC, considering the most relevant hurdles in each subtype of DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPancreatic NeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesGastrointestinal Tract

Stichwörter der Autor:innen

CAR T celladoptive cell therapyclinical trialsdigestive tract cancer

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Marc Wehrli, Marcela V Maus

Förderung

  • NCI NIH HHS

Zitieren

APA

Kronig, M. N., Wehrli, M., Salas-Benito, D., & Maus, M. V. (2023). “Hurdles race for CAR T ‐cell therapy in digestive tract cancer”. Immunological Reviews, 320(1), 100-119. https://doi.org/10.1111/imr.13273

Vancouver

Kronig MN, Wehrli M, Salas-Benito D, Maus MV. “Hurdles race for CAR T ‐cell therapy in digestive tract cancer”. Immunological Reviews. 2023;320(1):100-119. doi:10.1111/imr.13273

BibTeX
@article{Kronig2023,
  author = {Kronig, Marie-Noelle and Wehrli, Marc and Salas-Benito, Diego and Maus, Marcela V},
  title = {“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”},
  journal = {Immunological Reviews},
  year = {2023},
  volume = {320},
  number = {1},
  pages = {100--119},
  doi = {10.1111/imr.13273}
}
Kostenlos starten →